SCHEMBL19036616

SCHEMBL19036616

COc1ccc(N(CC(F)(F)F)C(=O)I)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.42
BCL2A1 Q16548 2/20 0.40
RNF4 P78317 1/20 0.40
RORC P51449 1/20 0.39
TP53 P04637 2/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
ESR2 Q92731 1/20 0.39
NOX1 Q9Y5S8 1/20 0.39
ALDH1A1 P00352 1/20 0.39
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
CES2 O00748 1/20 0.38
CES1 P23141 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11725723 0.84 CA1 (0.43) TSHRBCL2A1RNF4RORCTP53
SCHEMBL1429908 0.71 RNF4 (0.45) TSHRBCL2A1RNF4ALDH1A1KEAP1
SCHEMBL28467162 0.69 ESR1 (0.46) TSHRRORCNPC1ESR2ALDH1A1
SCHEMBL15984777 0.68 SMN1; SMN2 (0.62) TSHRBCL2A1RNF4MAPTSMN1; SMN2
SCHEMBL5702218 0.68 RNF4 (0.51) TSHRBCL2A1RNF4SMN1; SMN2ALDH1A1
SCHEMBL28963771 0.68 TSHR (0.41) TSHRBCL2A1TP53MAPTSMN1; SMN2
SCHEMBL5622935 0.68 KEAP1 (0.61) RORCMAPTALDH1A1KEAP1NFE2L2
SCHEMBL8030070 0.67 MMP8 (0.41) TSHRBCL2A1RNF4TRPM8
SCHEMBL24193445 0.67 CA1 (0.43) TP53MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL11875667 0.67 SMN1; SMN2 (0.47) TSHRBCL2A1RNF4TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3184527-A1 2,6-DIOXO,-2,3-DIHYDRO-1H-PURINE COMPOUNDS USEFUL FOR TREATING DISORDERS RELATED TO THE ACTIVITY OF THE TRPA1 CHANNEL Hydra Biosciences, Inc. (US) 2017-06-28 EP disclosed